Allgens(SH:688613) Sou Hu Cai Jing·2025-11-01 19:21Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and significant shareholder changes, while showing positive financial performance in its recent quarterly report [1][3][5]. Shareholder Changes - BioVeda China RMB Investment Limited reduced its holdings by 966,600 shares, accounting for 0.7055% of the total share capital, during a period when the company's stock price fell by 14.62% [3][6]. - As of September 30, 2025, the number of shareholders increased to 9,862, a rise of 15.44% compared to June 30, 2025, with the average shareholding decreasing from 16,000 shares to 13,900 shares [4][8]. Financial Performance - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [5][8]. - In the third quarter alone, the company achieved a main revenue of 56.02 million yuan, reflecting a year-on-year growth of 16.54%, and a net profit of 5.97 million yuan, which is a 237.64% increase compared to the same period last year [5][8]. - The company's debt ratio stands at 6.22%, with a gross profit margin of 68.9% [5]. Company Announcements - Aojing Medical has completed the reduction plan by BioVeda, which involved selling 1,355,515 shares at prices ranging from 23.00 to 28.12 yuan per share, totaling approximately 33.55 million yuan [6][8]. - The company has concluded the fundraising project for "Mineralized Collagen/Polyester Artificial Bone and Collagen Sponge R&D," with a surplus of 523,800 yuan intended for permanent replenishment of working capital [7][8].